Review
doi: 10.1016/j.phrs.2009.01.010.
Epub 2009 Jan 31.
Emerging role of PPAR ligands in the management of diabetic nephropathy
Affiliations
- PMID: 19646656
- DOI: 10.1016/j.phrs.2009.01.010
Item in Clipboard
Review
Emerging role of PPAR ligands in the management of diabetic nephropathy
Pharmacol Res.
2009 Sep.
Abstract
Diabetic nephropathy is a leading cause of morbidity and mortality in hyperglycemic patients. Angiotensin converting enzyme inhibitors and angiotensin-II AT(1) receptor blockers are currently employed to treat patients with diabetic nephropathy; but these agents are considered to be inadequate to control the symptoms of diabetic nephropathy. Recent studies suggest that PPAR ligands are promising agents to prevent the progression of diabetic nephropathy. In the present review, we discussed the novel role of PPARalpha and PPARgamma agonists in the management of diabetic nephropathy.
Similar articles
-
Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Nat Clin Pract Nephrol. 2005 Nov;1(1):33-43. doi: 10.1038/ncpneph0029. Nat Clin Pract Nephrol. 2005. PMID: 16932362 Review.
-
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?Pharmacol Res. 2012 Apr;65(4):430-6. doi: 10.1016/j.phrs.2012.01.004. Epub 2012 Jan 21. Pharmacol Res. 2012. PMID: 22285932 Review.
-
PPAR agonists in diabetic nephropathy.Nephrol Dial Transplant. 2007 Jul;22(7):2095; author reply 2095-6. doi: 10.1093/ndt/gfm057. Epub 2007 Feb 22. Nephrol Dial Transplant. 2007. PMID: 17317713 No abstract available.
-
Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.Pharmacol Res. 2009 Jul;60(1):24-32. doi: 10.1016/j.phrs.2009.02.002. Epub 2009 Feb 14. Pharmacol Res. 2009. PMID: 19427582 Review.
-
PPAR ligands: are they potential agents for cardiovascular disorders?Pharmacology. 2007;80(1):1-10. doi: 10.1159/000102594. Epub 2007 May 10. Pharmacology. 2007. PMID: 17496434 Review.
Cited by
-
A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy.PPAR Res. 2018 Jul 19;2018:7916953. doi: 10.1155/2018/7916953. eCollection 2018. PPAR Res. 2018. PMID: 30105051 Free PMC article.
-
Nuclear hormone receptors in diabetic nephropathy.Nat Rev Nephrol. 2010 Jun;6(6):342-51. doi: 10.1038/nrneph.2010.56. Epub 2010 Apr 27. Nat Rev Nephrol. 2010. PMID: 20421884 Review.
-
Identification of genes and signaling pathways associated with diabetic neuropathy using a weighted correlation network analysis: A consort study.Medicine (Baltimore). 2016 Nov;95(47):e5443. doi: 10.1097/MD.0000000000005443. Medicine (Baltimore). 2016. PMID: 27893688 Free PMC article.
-
Peroxisome Proliferator-Activated Receptor Alpha Stimulation Preserves Renal Tight Junction Components in a Rat Model of Early-Stage Diabetic Nephropathy.Int J Mol Sci. 2024 Dec 7;25(23):13152. doi: 10.3390/ijms252313152. Int J Mol Sci. 2024. PMID: 39684861 Free PMC article.
-
Protective Effects of Total Glycoside From Rehmannia glutinosa Leaves on Diabetic Nephropathy Rats via Regulating the Metabolic Profiling and Modulating the TGF-β1 and Wnt/β-Catenin Signaling Pathway.Front Pharmacol. 2018 Sep 11;9:1012. doi: 10.3389/fphar.2018.01012. eCollection 2018. Front Pharmacol. 2018. PMID: 30271343 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
